NK cells with antibodies for blood cancer
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a treatment using natural killer (NK) cells combined with antibodies to fight a type of blood cancer called acute myeloid leukemia (AML). It is for people whose AML has come back or not improved with standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have acute myeloid leukemia (AML) that has returned or not responded to treatment.
- Your cancer cells show a certain level of disease in your bone marrow.
- Your liver, kidney, and heart functions are within acceptable ranges.
- You have no active infections, including hepatitis B, hepatitis C, or HIV.
- You have not had CAR-T cell therapy or other genetically modified T cell treatments before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new treatment using natural killer (NK) cells that are specially created in the lab to find and attack cancer cells that have a protein called CD5 on their surface. The treatment is given along with chemotherapy to help the NK cells work better. It may be an option for people with certain types of T-cell lymphoma or leukemia that have not responded to other treatments.
This trial tests a new type of cell therapy called NKG2D CAR-T for people with AML that has not responded to standard treatment or has come back. It aims to use your own immune cells, modified to attack the leukemia, to help you achieve remission.
This trial tests a new type of immunotherapy using special immune cells (NK cells) that target the CD123 marker found on AML cells. It may help people whose AML has not responded to standard treatments and who have a healthy donor available.
This trial tests whether giving specially trained natural killer (NK) cells after a stem cell transplant can help prevent relapse in people with high-risk blood cancers like AML, MDS, or MDS/MPN. You receive one infusion of these cells about a week after your transplant.
This trial tests if giving special immune cells from a donor can clear leftover leukemia cells in patients who are in remission but still have traces of cancer after chemotherapy.
This trial tests a customized immune-cell treatment (NK cells) for certain blood cancers to try to control or eliminate cancer cells. You may qualify if your cancer has come back, did not fully respond, or has higher risk features.
Hear when a new Hematological Malignancies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.